Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
The "Halftime Report" traders give their final trades of the show.
As investors await word on U.S. interest rate increases, quantitative easing certainly seems to be helping stock markets in Europe and Japan.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Monday: Stifel, Express Scripts, SunPower & more.
U.S. stocks pulled back from Friday's records to close narrowly mixed ahead of Fed Chair Janet Yellen's remarks over the next two days.
U.S. stock index futures signaled a lower open on Monday as uncertainty surrounded Greece's deal with its euro zone creditors.
With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.
U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.
Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.
Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.
From a U.S. trading perspective, here are the ways to play the strengthening dollar of 2015.
Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.
One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.
Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.
Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.
Check out which companies are making headlines after the bell Tuesday: Cal-Maine Foods, Gilead & Sony.